Researchers at Sutter Health have launched a biobank registry aimed at LATE, or limbic-predominant age-related TDP-43 encephalopathy, a form of dementia that can resemble Alzheimer's disease but stems from a different biological process. The LATE Biobank Registry lets Sutter researchers study biological samples and clinical data from patients who meet clinical criteria for the condition, collecting material over the course of routine care.
LATE is linked to an abnormal buildup of the protein TDP-43 in brain areas critical to memory. Unlike Alzheimer's, it currently has no specific biomarkers and no known treatments. That gap matters because, as biomarker testing makes Alzheimer's easier to identify, some patients whose memory loss looks like Alzheimer's test negative for the amyloid and tau markers associated with that disease. Dr. Shawn Kile, chair of Sutter Health's Advanced Neuroscience Service Line, said some of these patients may instead have LATE.
Autopsy studies cited by Dr. Kile suggest LATE pathology shows up in about 40 percent of people age 80 and older. Dr. Kile said it is not yet clear whether the pathology is the primary driver of cognitive decline in some cases or a co-existing pathology in others, which is why he considers it important to understand. By collecting blood and cerebrospinal fluid from clinically suspected cases over time, the registry aims to close knowledge gaps and move toward a biomarker-driven diagnosis and more targeted treatments.
The registry opened for enrollment in May 2026. At the time Dr. Kile submitted his abstract, researchers had identified 21 eligible patients, and six had consented to take part. Patients can enroll through participating Sutter Health affiliates across California. Dr. Kile will present early findings from the registry on Nov. 18 at the Clinical Trials on Alzheimer's Disease conference in Boston. Sutter also sees the registry as a cohort for future clinical trials of treatments targeting TDP-43.